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Summary
Purpose: A wide variety of fiuorouracil (FU)-plus-leucovorin
(LV) dose schedules are in clinical use for the treatment of
advanced colorectal cancer. Only the monthly low-dose LV-
plus-FU regimen, as used by the North Central Cancer Treat-
ment Group, has demonstrated a lasting survival benefit as
opposed to FU alone (J Clin Oncol 1989; 7: 1407-1417). The
Swiss Cancer Group adopted this regimen for a confirmatory
phase III trial but used the same dose-intensity of fiuorouracil
in both treatment arms.
Patients and methods: Patients with inoperable or metastatic
colorectal cancer were randomized to receive monthly FU
400 mg/m2/day plus LV 20 mg/m2/day as intravenous push
daily for five days, or FU alone.
Results: Three hundred nine of the 310 patients randomized
were eligible and included in the analysis. The objective re-
sponse rate for patients with measurable disease was 9% with
FU alone and 22% with FU-plus-LV (P = 0.0001). The median
progression-free survival was 3.9 versus 6.2 months (P = 0.003)
and the overall survival 10 versus 12.4 months (P = 0.02). The
major prognostic factors for survival were performance status,
weight loss, and disease symptoms. WHO > 2 toxicity, consist-
ing of stomatitis (P = 0.001), diarrhea (P - 0.001), and nausea
(P = 0.001), was more pronounced for FU-plus-LV, without
fatal events.
Conclusions: This is the largest published randomized trial
to compare FU-plus-LV to FU alone in advanced colorectal
cancer. It confirms the survival benefit obtained from biomo-
dulating monthly FU with low-dose LV. The toxic effects of
FU-plus-LV were acceptable to most patients, and they re-
sponded well to FU dose reductions. In the absence of an ideal
dose-intense FU monotherapy regimen, monthly FU with low-
dose LV provides a simple and economical means by which to
achieve adequate FU efficacy in the treatment of advanced
colorectal cancer.
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Introduction
Fiuorouracil (FU) is still the standard treatment for
advanced colorectal cancer, against which new drugs
and combinations have to be compared. However, de-
spite decades of clinical experience with this drug, its
optimal administration schedule has yet to be deter-
mined [1]. Biochemical modulation with folinic acid
(leucovorin [LV]) has been clearly shown to increase the
biological effect of FU. A meta-analysis of phase III
trials comparing different schedules of FU modulated
by LV versus FU alone has demonstrated the signifi-
cantly higher response rate of 23% for the combination
as opposed to 11% for FU monotherapy [2]. However,
this increase in response did not translate into a discern-
ible improvement of overall survival [2]. As for FU
alone, different schedules of FU-plus-LV are in clinical
use and were included in the meta-analysis.
The most popular administration schedules of FU-
plus-LV are the weekly regimens and daily-times-five
courses every 28 days (monthly regimen). A direct com-
parison of weekly and monthly FU-plus-LV administra-
tion has shown no clear advantage for one schedule over
the other [3]. Another open question is the LV dose
required to obtain optimal modulation of FU activity.
With the monthly regimen, low- and high-dose LV (20
and 200 mg/m2) have yielded similar results [4, 5], while
the situation is apparently more controversial with the
weekly regimen [6, 7]. An important aspect is the fact
that LVadds significantly to the costs of this treatment.
The only trial so far to demonstrate a lasting signifi-
cant survival benefit with FU and LV compared to FU
alone was published by Poon et al. of the North Central
Cancer Treatment Group (NCCTG)/Mayo Clinic [4, 5].
Their regimen in the modulated treatment arm was
monthly FU-plus-low-dose-LV, which led to both a
survival benefit and an improvement of various quality-
of-life (QoL) parameters. The study is unique because of
the beneficial effect from modulated FU on clinically
relevant endpoints and the use of a monthly FU-plus-
low-dose-LV schedule. Therefore, in 1991 the Swiss Group
for Clinical Cancer Research (SAKK) started this con-
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firmatory phase III trial in which FU was given monthly
at 400 mg/m2 for five days throughout the entire treat-
ment period to achieve equal FU dose intensity for both
treatment arms. This allows a direct assessment of the
biomodulatory effect of LV on FU. In the Poon study,
FU alone (500 mg/m2) was repeated every five weeks as
was FU (425 mg/m2)-plus-LV after the first two treat-
ment cycles [4]. Thus, the FU dose intensities in the
monotherapy arms of our study and the Mayo Clinic
trial were identical. We were reluctant to increase the
dose of modulated FU to 425 mg/m2, since FU at a
dose of 400 mg/m2 caused significant toxicity in our
randomized pilot study [8]. Furthermore, a fatality oc-
curred in a previous study of this group using FU alone
atadoseof450mg/m2[9].
Patients and methods
Eligibility criteria
Patients were required to have histologically-confirmed inoperable
locally advanced or metastatic colorectal cancer. Disease was defined
as either bidimensionally measurable or non- measurable. All patients
were ambulatory (Eastern Cooperative Oncology Group (ECOG) per-
formance status $ 3). Previous chemotherapy was not allowed except
for adjuvant chemotherapy which had been terminated ~2- one year
before study entry. Adequate organ function was required. All patients
provided voluntary informed consent. The study protocol was ap-
proved by the local ethics committees of the participating institutions.
Treatment
Patients were stratified according to the presence or absence of meas-
urable disease and disease symptoms and randomized to FU alone or
FU-plus-low-dose-LV. FU alone: FU was given by rapid IV push at
400 mg/m2/d for five consecutive days with courses repeated every 28
days. FU-plus-low-dose-LV: leucovorin was given at 20 mg/m2/day
immediately followed by FU at 400 mg/m2/day. Both drugs were given
by rapid IV bolus injection daily for five consecutive days with courses
repeated every four weeks. The FU dose was decreased by 25% if grade
3 toxicity according to WHO criteria had occurred in the previous
treatment cycle. Dose escalation of FU by 10% per step was recom-
mended in instances of non-hematological toxicity <grade 2 and nadir
blood counts of > 2000 leucocytes/ul and > 100,000 platelets/ul [10].
The intent was to escalate the FU dose to produce comparable toxicity
in the two treatment arms.
Endpoints and response criteria
Endpoints of the study were overall survival, lime-to-treatment-
failure, progression-free survival, objective response for patients with
measurable disease, palliative effects as suggested by Poon et al. [4],
and toxicity. Treatment failure was defined as cessation of treatment
because of disease progression, clinical deterioration, treatment re-
fusal, toxicity, or death. The type of first failure was evaluated and
recorded for each patient. Progression-free survival was defined as the
time between randomization and clinical deterioration, progression or
death. Patients who discontinued treatment by choice or because of
toxicity were followed and monitored for progression. The intervals
were calculated from day of randomization until occurrence of the
event. Complete response (CR) required the total disappearance of all
tumor initially observed, with no new areas of disease. Partial response
(PR) was defined as a greater than 50'/. reduction in the sum of the
products of the longest perpendicular diameters of all measurable
indicator lesions. Progressive disease (PD) was a greater than 25%
increase in the products of the longest perpendicular diameters of any
area of known malignant disease. Radiological tumor measurements
were performed at every second treatment cycle. At study entry, the
presence or absence of disease symptoms was assessed. At the start of
each treatment cycle the patient was asked whether these symptoms
were still present or had disappeared during study participation.
Statistical analysis
The computation of sample size was made with the aim of achieving
sufficient power for the comparison of the treatment arms in terms of
survival. Assuming an exponential survival distribution, a median
survival improvement from 30 to 45 weeks and, with the significance
level for the log-rank test set at 5% and the power at 90%, a target
number of 300 patients was estimated. The study was closed after the
accrual of 310 patients in November 1995. The efficacy analyses
included all eligible patients and used the 'intent-to-treat' approach.
The safety analysis included all treated patients. The chi-square or the
Fisher's exact tests were used for contingency tables (StatXact, Cytel
Corporation, Cambridge, MA). The Wilcoxon rank sum test was used
for ordered categorical tables (types of toxicities).
Time-to-treatment-failure (TTF), progression-free survival (PFS),
and overall survival (OS) were estimated according to the Kaplan-
Meier product limit method [11], The validity of the proportional
hazard assumption was tested [12] and since there was evidence of an
increasing hazard ratio over time for these parameters, the Gehan-
Wilcoxon was applied instead of the log-rank test for treatment com-
parison in terms of TTF, PFS and OS. The prognostic importance of
clinical variables with respect to progression-free survival and overall
survival was assessed using the log-rank test [13]. Stratified analyses to
adjust for covariates were calculated as described [4], This method of
covariate adjustment was used because of the treatment interactions
with the covariates, which prevented the use of an unstratified Cox
proportional hazards model. Of the two prospectively defined stratifi-
cation factors, measurability was not considered because of the small
number of patients with non-measurable disease. Unless otherwise
noted, significance indicated P-values $0.05. All f-values given are
two-sided. No adjustment for multiple comparisons was performed.
Results
Patient characteristics and treatment summary
Between 5 February 1991 and 20 November 1995, 310
patients were accrued to this trial. Only one patient was
ineligible, because FU had been given in the adjuvant
setting. Six patients were inevaluable for toxicity, since
they received no protocol treatment due to unexpected
deterioration of their physical conditions after random-
ization. The characteristics of the 309 eligible patients
are displayed in Table 1. The variables listed were dis-
tributed without significant differences between the two
treatment arms. The median age was 63 years (range 26-
82 years) in the monotherapy arm and 62 years (range
27-81 years) in the FU-plus-LVarm. Slightly fewer than
half of the patients had symptoms attributed to malig-
nant disease. Almost 90% of the patients had measurable
disease.
The median number of treatment cycles was 4 in the
FU monotherapy arm and six in the FU-plus-LV arm.
The protocol recommended intensification of the FU
dose (see 'Patients and methods') to produce equal tox-
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Table I. Characteristics of eligible patients. Table 2. Toxicity.
Characteristic FU alone, FU + LV, Toxicity
n = 157 (%) n = 152 (%)
Sex
Male
Female
Symptomatic
Measurable disease
Performance score (ECOG) 0.1
Weight loss in previous six months > 10%
Site of primary
Colon
Liver involvement
Multiple metastatic sites
Tumor-free interval < six months
Adjuvant chemotherapy
63
37
45
89
90
21
71
76
51
65
5
60
40
43
69
70
52
59
9
I
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Figure I. Mean cumulative dose of FU in the respective treatment arm.
icity in both treatment arms. FU doses were increased
^ 10% at least once in 41% of the patients in the mono-
therapy arm and in 31% of those in the FU-plus-LV arm
(P = 0.07). However, restricting the analysis to patients
without toxicity, the appropriate FU dose increase was
performed in only 23% and 20% of these patients,
respectively, suggesting a poor compliance with the
dose increase recommendations. FU doses were de-
creased > 10% at least once in 27% of the patients in
the monotherapy arm and in 57% of those in the FU-
plus-LV arm (P = 0.0001). The cumulative plot of the
dose received is displayed in Figure 1. In the monother-
apy arm, the dose intensity of FU remained largely
constant over the treatment period, suggesting a good
tolerance of the therapy. In the FU-plus-LV arm the dose
intensity of FU decreased slowly over time, suggesting
the impact of toxicity and the need for dose modifica-
tions. Since the treatment intervals remained largely
unaffected over time in both treatment arms it can be
Fu alone,
n = 155 (%)
Fu + LV.
n = 148 (%)
Stomatitis
1
2
3
4
Diarrhea
1
2
3
4
Nausea/vomiting
1
2
3
4
Alopecia
1
2
3
Other toxicity
1
2
3
4
19
12
3
0
22
14
5
1
32
15
1
1
5
3
1
12
17
7
1
0.0001"
0.0001
0.007
0.0001
0.0001
19
23
22
3
18
30
21
1
34
23
7
1
23
14
24
10
4
a
 Wilcoxon rank sum test significance level.
assumed that patients recovered from toxicity in
time.
Toxicity
due
Adding LV to FU resulted in a significant increase in
WHO grade ^ 2 stomatitis, diarrhea, nausea, alopecia,
and other, mainly hematological, toxic effects (Table 2).
Weekly blood counts were not required in this trial.
No fatal toxicities were observed. In 17 patients with
FU-alone treatment was discontinued due to refusal or
toxicity compared to 26 patients on FU-plus-LV (P =
0.14).
Progression-free survival and time-to-treatment-failure
Two hundred ninety-seven patients had progressed or
died at the time of this analysis. The distribution of
progression-free survival according to treatment regimen
is illustrated in Figure 2. Events occurred later with the
combined treatment, but this effect disappeared after
about 18 months. The median progression-free survival
time was 3.9 months for FU and 6.2 months for FU-
plus-LV (P - 0.003). The six-month failure-free actuarial
survival was 38% for FU and 52% for FU-plus-LV.
Performance status, weight loss, symptoms at study en-
try, and tumor-free interval were the factors most signifi-
cantly associated with progression-free survival. The sig-
nificant advantage of FU-plus-LV was confirmed adjust-
ing for disease measurability, symptoms, and weight loss
(stratified test: 8.18, P < 0.01). The median time-to-
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Figure 2. Progression-free survival according to treatment arm. The
f-value refers to the Gehan-Wilcoxon test.
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Figure 3. Overall survival according to treatment arm. The P-value
refers to the Gehan-Wilcoxon test.
Table 3. Response rates: Patients with measurable disease at baseline. Table 4. Covariates predictive for survival.
Clincal response FU alone,
n - 139 (%)
FU + LV,
n - 134 (%)
Factor Deaths/total
CR + PR 9
95% confidence interval 5-13
SD 29
PD 40
Inevaluable for response 22
22
15-29
34
25
19
treatment-failure was 3.9 months for FU and 5.5 months
for FU-plus-LV (P - 0.02). As expected, time-to-treat-
ment-failure roughly corresponded to the median num-
ber of cycles in the respective treatment arm.
Objective tumor response
Clinical response was evaluated in the 273 patients with
measurable disease (Table 3). FU-plus-LV yielded a
significantly higher response rate than FU alone (P -
0.0002). A conservative approach for response evaluation
was chosen since all measurable but non-evaluable pa-
tients entered the denominator as unresponsive to treat-
ment. The median response duration was seven months
for FU and 10 months for FU-plus-LV (/> = 0.46).
Overall survival
Two hundred fifty patients have died at the time of this
analysis. The median follow-up for patients while alive
was three years. FU-plus-low-dose-LV provided a sig-
nificant survival advantage over FU alone (P - 0.02).
The median overall survival was 12.4 and 10 months and
the one-year actuarial survival 53% and 43%, respec-
tively. Survival distributions for the study patients ac-
cording to treatment arm are illustrated in Figure 3.
Prognostic covariates predictive of overall survival are
summarized in Table 4. Performance status, weight loss,
symptoms at study entry, and tumor-free interval were
the factors most significantly associated with overall
Symptomatic
No
Yes
Performance status
0
> 1
Weight loss (%)
< 5 %
Tumor free interval11
< six months
> six months
Peritoneal involvement
Yes
No
Age group
< 60 years
> 60 years
Measurable disease
No
Yes
Site of primary
Colon
Rectum
Sex
Female
Male
Lung involvement
Yes
No
Liver involvement
Yes
No
126/174
124/135
116/154
134/155
137/177
113/132
157/192
93/117
53/62
197/247
98/121
152/188
28/36
222/273
181/217
69/92
95/119
155/190
64/75
186/234
183/226
67/83
Median
survival
(days)
486
256
486
261
455
240
283
439
252
373
382
304
376
336
320
382
335
352
355
350
328
434
Two-sided
log-rank
(/^-values)
0.0001
0.0001
0.0001
0.0001
0.0001
0.0001
0.001
0.001
0.008
0.008
0.03
0.03
0.07
0.07
NS
NS
NS
NS
NS
NS
NS
NS
a
 Time from diagnosis of primary until progression.
Abbreviation: NS - not significant.
survival. When adjusted for performance status, weight
loss, and symptoms at study entry, the significant sur-
vival advantage of FU-plus-LV was confirmed (stratified
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Table 5. Exploratory evaluation of impact of toxicity on survival
according to treatment.
Treatment arm
Stomatitis
FU
FU + LV
Diarrhea
FU
FU + LV
Nausea/vomiting
FU
FU + LV
Overall survival,
(WHO) grade
< 2 (months)
9.3
11.5
8.8
10.5
9.9
14.7
Table 6. Comparative palliative effect.
Effect
Disease symptoms
No. evaluable
% disappeared
Gain of weight gain :
No. evaluable
% improved
FU
69
42
151
38
Improvement in performance
status
No. evaluable
% better
% equal
% worse
155
27
59
14
toxicity
~$- 2 (months)
15.4
14.4
19.8
14.9
11.6
10.5
FU + LV
63
65
146
26
148
27
63
10
Two-sided
log-rank
(/•-values)
0.04
0.04
0.006
0.06
0.07
0.01
f-value
(chi-square test)
0.009
0.03
0.62
test: 7.43, P < 0.01). We were also interested in whether
patients with relevant toxicity had more benefit from the
treatment or whether, on the contrary, toxicity had a
negative impact on outcome. In both treatment arms,
patients with WHO grade ^ 2 diarrhea or stomatitis
lived longer than patients without toxicity (Table 5).
However, nausea and vomiting had a negative impact
on survival in the FU-plus-LVarm.
Palliative effects
Improvement in performance status, symptomatic im-
provement, and weight gain were proposed as surrogate
quality-of-life measuremens in the study of Poon et al.
[4]. Our results using the same parameters are summar-
ized in Table 6. We confirmed the beneficial effect of FU
plus LVon disease symptoms, but performance status was
not affected. Weight was negatively affected by FU-plus-
LV, suggesting an impact of gastrointestinal toxicity.
Discussion
Despite a convincing biochemical rationale for the bio-
modulation of FU with LV, only a single randomized
trial has thus far shown a lasting survival benefit from
FU-plus-LV over FU alone in advanced colorectal can-
cer [4, 5]. Additional attractive features of modulated
FU in that study were the demonstration of a beneficial
impact on different quality-of-life parameters and the
use of an economical LV dose. Thus, the monthly FU-
and-low-dose-LV regimen favored by the NCCTG/
Mayo Clinic team seems to be the most attractive che-
motherapy for advanced colorectal cancer at this point.
However, a meta-analysis of randomized trials com-
paring FU alone to FU-plus-LV in advanced colorectal
cancer failed to confirm a survival benefit for the combi-
nation despite a significantly higher response rate. For
this meta-analysis, trials using widely differing dose
schedules of FU and LV were lumped together. The
assumption that these regimens have similar therapeutic
potency might not be valid, and the effect of trials using
a potent FU-plus- LV regimen could have been blurred
by trials using an ineffective regimen. It has been specu-
lated that even small differences in the duration of the
FU injection could affect outcome in terms of efficacy
and toxicity [1]. In addition, individual patient data
from the NCCTG/Mayo Clinic were not included in
the meta-analysis. A post hoc analysis including the
NCCTG/Mayo Clinic overall results changed the haz-
ard ratio and the p-value for a survival benefit from
modulated FU from 0.97 (P = 0.57) to 0.92 (P = 0.14).
This indirect evidence of the superiority of monthly FU-
plus-low-dose-LV over FU alone rendered a second
independent trial testing the same hypothesis highly
desirable.
This is the largest study published to date of a compar-
ison of FU-plus-LV and FU alone in advanced colorectal
cancer. Despite minor schedule and dosing differences
between it and the NCCTG/Mayo Clinic trial, we ob-
tained very similar results in terms of overall survival
and progression-free survival. This result is particularly
reassuring, since close to 90% of our patients had meas-
urable disease, which was identified as an adverse prog-
nostic factor in both studies. Another important adverse
prognostic factor in our study was the presence of
disease symptoms at the start of study treatment. This
result provides indirect evidence that it might be detri-
mental to postpone treatment in colorectal cancer until
symptoms occur. This is in agreement with the findings
of the NORDIC group, which randomized patients to
early treatment or treatment delay until symptoms oc-
curred and thus was not affected by a length of time bias
[14].
We chose the same initial dose level of FU for both
treatment arms of our study to assess the true impact of
LV in terms of tumor response and toxicity. Despite in
vitro data suggesting the need for LV serum concentra-
tions of > 10 uM for optimal FU biomodulation, the
impact of this low LV dose on the toxicity of FU was
striking. In addition, the NCCTG/Mayo Clinic com-
pared 20 mg/m2/day LV to 200 mg/m2/day LV in
combination with FU and found no increased clinical
effect with the higher LV dose [4, 5]. The significant
toxicity of monthly FU-plus-low-dose-LV [4, 5. 15],
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however, leads to the question of whether this grade of
toxicity is acceptable considering the modest survival
benefit with this palliative treatment. Although disease
symptoms were significantly more often abolished by
the combined treatment, we were not able to confirm a
clinical benefit for FU-plus-LV over FU monotherapy in
terms of weight gain and improvement of performance
status as described by Poon et al. [4]. However, treat-
ment refusal due to toxicity was rare in both treatment
arms and the median number of treatment cycles was
six in the combination arm compared to four with
FU alone, suggesting that patients accepted the toxicity
of the combined regimen. This might have been helped
by the fact that FU dose reductions led to a decrease
of toxicity during the course of treatment with FU-
plus-LV. Interestingly, in our evaluation patients suffering
5= grade 2 stomatitis or diarrhea had longer survivals
in both treatment arms. The median survival doubled
for patients treated with FU alone suffering ^ grade 2
diarrhea. This is even more surprising in view of the
possible adverse impact of this toxicity pattern in terms
of nutritional and performance status. Being aware of the
bias of post hoc comparisons, these results seem to
suggest a critical dose level for FU, which is associated
with both efficacy and toxicity. Nausea and vomiting had
a negative impact on overall survival in patients treated
with FU-plus-LV. This could have been related to the fact
that peritoneal disease, which was associated with this
type of toxicity, was an adverse prognostic factor for
overall survival.
A crucial question is whether the effect seen for FU-
plus-LV could also be obtained by increasing the dose
intensity of FU alone [16]. Valone et al. of the NCOG
compared a dose-intensive FU regimen to monthly FU-
plus-LV (200 mg/m2/day) in advanced colorectal cancer
[17]. The dose intensive FU regimen led to higher hema-
tological and non-hematological toxicity and the authors
state that FU-plus-LV had the better therapeutic ratio of
benefits versus toxicity. Laufman et al. designed an
interesting randomized, double-blind study to achieve
equitoxicity between FU monotherapy and FU-plus-
high-dose-oral-LV [18]. They found a higher response
rate with the combination, which did not translate into
prolonged survival. The equitoxic FU doses were 472
mg/rrr/wk in the monotherapy and 420 mg/m2/wk in
the combined treatment arm. The dose intensity of FU
was 500 mg/m2/wk for both treatment arms in our study.
This suggests that our FU-plus-LV arm had a higher
relative FU dose intensity than the FU monotherapy
arm. Although dose intensification was recommended
in the absence of relevant toxicity, these recommenda-
tions were only observed in a small proportion of the
eligible patients. Many clinicians obviously considered a
dose increase too risky for their patients. In other cases,
FU had to be discontinued due to treatment failure
before an adequate toxicity level was achieved.
It is debatable for many published trials comparing
FU alone to FU-plus-LV whether the optimal dose
intensity of the FU monotherapy arm has been achieved
[16]. Surprisingly, this question has never been resolved
although FU was introduced into clinical use four deca-
des ago. Thus, it is doubtful that this problem will be
solved in the near future. We would reason that modu-
lating monthly FU with low-dose LV is a feasible and
pragmatic means by which to increase the efficacy of FU.
This approach is safe, since we observed no fatalities
in our large trial and the toxicity of this treatment re-
sponded well to FU dose modifications or to the omis-
sion of LV. However, the patients should be informed
about the greater chances of their suffering side effects
from FU-plus-LV and be given the option of making an
informed decision against the use of LV. The monetary
argument against LV loses importance in view of the
falling prices for this drug and the low LV dose used in
this regimen. Despite the vast experience with FU alone
and in combination with LV in the treatment of advanced
colorectal cancer, the question of the optimal FU dose
schedule still needs to be answered.
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